Premium
Hypocholesterolemic effects of soyasaponins and soyasapogenol B
Author(s) -
Smith James D,
Salyer Joe,
Esawarnanadam Satchithanandam,
Lee SunOk
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.980.6
Subject(s) - aglycone , triglyceride , cholesterol , chemistry , bioavailability , endocrinology , medicine , biochemistry , pharmacology , stereochemistry , glycoside
Elevated blood cholesterol levels are associated with the development of heart disease. Soyasaponins have been suggested as a factor capable of decreasing plasma cholesterol. Soyasaponins are naturally occurring triterpenoids found in soybeans and sugars are cleaved from soyasaponins in the digestive tract leaving the aglycone form, soyasapogenol B. The objectives of this study are to determine cholesterol‐lowering efficacy and bioavailability of soyasapogenol B and soyasaponins. Forty‐eight hamsters were assigned to one of four dietary treatment groups and fed for 4 weeks; 1) low fat control (LFC), 2) high fat control (HFC), 3) high fat diet with soyasapogenol B (SPG, 0.9 mmol/kg diet), 4) high fat diet with group B soyasaponins (SSP, 1.8 mmol/kg diet). When caloric intake was accounted for, the SPG group had a significantly lower total cholesterol concentration than the HFC groups (P<0.05). Compared with high fat control, soyasaponin and soyasapogenol B treatments were shown to decrease non‐HDL and triglyceride cholesterol levels, but the decrease was not significant. SPG had a significantly greater fecal excretion of soyasapogenol B than the SSP group (P<0.05). The soyasapogenol B group demonstrated a greater reduction in cholesterol levels due to the bioactivity of the aglycone form. Funded by EPSCoR‐P3 Grant, Arkansas Center for Plant‐Powered Production, University of Arkansas.